|Locus||Chr. 19 p13.3|
|anti-Müllerian hormone receptor, type II|
|Locus||Chr. 12 q13|
Anti-Müllerian hormone also known as AMH is a protein that, in humans, is encoded by the AMH gene. It inhibits the development of the Müllerian ducts (paramesonephric ducts) in the male embryo. It has also been called Müllerian inhibiting factor (MIF), Müllerian-inhibiting hormone (MIH), Müllerian-inhibiting substance (MIS), and Anti-paramesonephric hormone (APH). It is named after Johannes Peter Müller.
- 1 Species distribution
- 2 Sources
- 3 Structure
- 4 Gene
- 5 Function
- 6 Pathology
- 7 Blood levels
- 8 Clinical usage
- 9 See also
- 10 References
In mammals, AMH prevents the development of the Müllerian ducts into the uterus and other Müllerian structures. The effect is ipsilateral, that is each testis suppresses Müllerian development only on its own side. In humans, this action takes place during the first 8 weeks of gestation. If no hormone is produced from the gonads, the Müllerian ducts automatically develop, while the Wolffian ducts, which are responsible for male reproductive parts, automatically die. Amounts of AMH that are measurable in the blood vary by age and sex. AMH works by interacting with specific receptors on the surfaces of the cells of target tissues. The best-known and most specific effect, mediated through the AMH type II receptors, includes programmed cell death (apoptosis) of the target tissue (the fetal Müllerian ducts).
AMH is expressed by granulosa cells of the ovary during the reproductive years, and limits the formation of primary follicles by inhibiting excessive follicular recruitment by FSH. Some authorities suggest it is a measure of certain aspects of ovarian function, useful in assessing conditions such as polycystic ovary syndrome and premature ovarian failure. It is useful to predict a poor ovarian response in in vitro fertilization (IVF), but it does not appear to add any predictive information about success rates of an already established pregnancy after IVF. Additionally, AMH levels are used to determine a women's remaining egg supply.
AMH production by the Sertoli cells of the testes remains high throughout childhood in males but declines to low levels during puberty and adult life. AMH has been shown to regulate production of sex hormones, and changing AMH levels (rising in females, falling in males) may be involved in the onset of puberty in both sexes. Functional AMH receptors have also been found to be expressed on neurons in the brains of embryonic mice, and are thought to play a role in sexually dimorphic brain development and consequent development of gender-specific behaviours.
In men, inadequate embryonal AMH activity can lead to the Persistent Müllerian duct syndrome (PMDS), in which a rudimentary uterus is present and testes are usually undescended. The AMH gene (AMH) or the gene for its receptor (AMH-RII) are usually abnormal. AMH measurements have also become widely used in the evaluation of testicular presence and function in infants with intersex conditions, ambiguous genitalia, and cryptorchidism.
In healthy females AMH is either just detectable or undetectable in cord blood at birth and demonstrates a marked rise by three months of age; while still detectable it falls until four years of age before rising linearly until eight years of age remaining fairly constant from mid-childhood to early adulthood – it does not change significantly during puberty. The rise during childhood and adolescence is likely reflective of different stages of follicle development. From 25 years of age AMH declines to undetectable levels at menopause.
The standard measurement of AMH follows the Generation II assay. This should give the same values as the previously used IBC assay, but AMH values from the previously used DSL assay should be multiplied with 1.39 to conform to current standards because it used different antibodies.
Weak evidence suggests that AMH should be measured only in the early follicular phase because of variation over the menstrual cycle. Also, AMH levels decrease under current use of oral contraceptives and current tobacco smoking.
|Younger than 24 months||ng/mL||Less than 5|
|pmol/l||Less than 35|
|24 months to 12 years||ng/mL||Less than 10|
|pmol/l||Less than 70|
|13–45 years||ng/mL||1 to 10|
|pmol/l||7 to 70|
|More than 45 years||ng/mL||Less than 1|
|pmol/l||Less than 7|
|Younger than 24 months||ng/mL||15 to 500|
|pmol/l||100 to 3500|
|24 months to 12 years||ng/mL||7 to 240|
|pmol/l||50 to 1700|
|More than 12 years||ng/mL||0.7 to 20|
|pmol/l||5 to 140|
AMH measurements may be less accurate if the person being measured is vitamin D deficient.
In vitro fertilization
According to NICE guidelines of in vitro fertilization, an anti-Müllerian hormone level of less than or equal to 5.4 pmol/l (0.8 ng/mL) predicts a low response to ovarian hyperstimulation, while a level greater than or equal to 25.0 pmol/l (3.6 ng/mL) predicts a high response. Other cut-off values found in the literature vary between 0.7 and 20 pmol/l (0.1 and 2.97 ng/ml) for low response to ovarian hyperstimulation. Subsequently, higher AMH levels are associated with greater chance of live birth after IVF, even after adjusting for age. AMH can thereby be used to rationalise the programme of ovulation induction and decisions about the number of embryos to transfer in assisted reproduction techniques to maximise pregnancy success rates whilst minimising the risk of ovarian hyperstimulation syndrome (OHSS) AMH can predict an excessive response in ovarian hyperstimulation with a sensitivity and specificity of 82% and 76%, respectively.
Measuring AMH alone may be misleading as high levels occur in conditions like polycystic ovarian syndrome and therefore AMH levels should be considered in conjunction with a transvaginal scan of the ovaries to assess antral follicle count and ovarian volume.
General fertility assessment
Comparison of an individual's AMH level with respect to average levels is also useful in fertility assessment, as it provides a guide to ovarian reserve and identifies women that may need to consider either egg freezing or trying for a pregnancy sooner rather than later if their long-term future fertility is poor. A higher level of anti-Müllerian hormone when tested in women in the general population has been found to have a positive correlation with natural fertility in women aged 30–44 aiming to conceive spontaneously, even after adjusting for age. However, this correlation was not found in a comparable study of younger women (aged 20 to 35 years).
Women with cancer
In women with cancer, radiation therapy and chemotherapy can damage the ovarian reserve. In such cases, a pre-treatment AMH is useful in predicting the long-term post-chemotherapy loss of ovarian function, which may indicate fertility preservation strategies such as oocyte cryopreservation. A post-treatment AMH is associated with decreased fertility.
Granulosa cell tumors of the ovary secrete AMH, and AMH testing has a sensitivity ranging between 76 and 93% in diagnosing such tumors. AMH is also useful in diagnosing recurrence of granulosa cell tumors.
Potential future usage
AMH has been synthesized. Its ability to inhibit growth of tissue derived from the Müllerian ducts has raised hopes of usefulness in the treatment of a variety of medical conditions including endometriosis, adenomyosis, and uterine cancer. Research is underway in several laboratories. If there were more standardized AMH assays, it could potentially be used as a biomarker of polycystic ovary syndrome.
- Sexual differentiation
- Anti-Müllerian hormone receptor
- Alfred Jost discoverer.
- PMDS (Persistent Müllerian Duct Syndrome)
- Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP (June 1986). "Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells". Cell 45 (5): 685–98. doi:10.1016/0092-8674(86)90783-X. PMID 3754790.
- Behringer RR (1994). "The in vivo roles of müllerian-inhibiting substance". Curr. Top. Dev. Biol. Current Topics in Developmental Biology 29: 171–87. doi:10.1016/S0070-2153(08)60550-5. ISBN 978-0-12-153129-4. PMID 7828438.
- Minkoff, Eli; Baker, Pamela (2004). Biology Today: An Issues Approach (Third Edition ed.). New York: Garland Science. p. 296. ISBN 1136838759.
-  Hampl, R.; Šnajderová, M.; Mardešić, T. (2011). "Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve". Physiological research / Academia Scientiarum Bohemoslovaca 60 (2): 217–223. PMID 21114374.
- Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizard R, Carré-Eusèbe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY (December 1995). "Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor". Nat. Genet. 11 (4): 382–8. doi:10.1038/ng1295-382. PMID 7493017.
- Page 1114 in: Walter F., PhD. Boron (2003). Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. p. 1300. ISBN 1-4160-2328-3.
- An Introduction to Behavioral Endocrinology, Randy J Nelson, 3rd edition, Sinauer
- Dewailly, D.; Andersen, C. Y.; Balen, A.; Broekmans, F.; Dilaver, N.; Fanchin, R.; Griesinger, G.; Kelsey, T. W.; La Marca, A.; Lambalk, C.; Mason, H.; Nelson, S. M.; Visser, J. A.; Wallace, W. H.; Anderson, R. A. (2014). "The physiology and clinical utility of anti-Müllerian hormone in women". Human Reproduction Update 20 (3): 370–385. doi:10.1093/humupd/dmt062. ISSN 1355-4786. PMID 24430863.
- Weenen C, Laven J, Von Bergh A, Cranfield M, Groome N, Visser J, Kramer P, Fauser B, Themmen A (2004). "Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment" (abstract). Mol Hum Reprod 10 (2): 77–83. doi:10.1093/molehr/gah015. PMID 14742691.
- Broer SJ at al (2011). "Anti-müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women". J Clin Endocrinol Metab 96 (8): 2532–9. doi:10.1210/jc.2010-2776. PMID 21613357.
- Visser J, de Jong F, Laven J, Themmen A (2006). "Anti-Müllerian hormone: a new marker for ovarian function". Reproduction 131 (1): 1–9. doi:10.1530/rep.1.00529. PMID 16388003.
- Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJ, Mol BW, Broekmans FJ (2013). "Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach". Human Reproduction Update 19 (1): 26–36. doi:10.1093/humupd/dms041. PMID 23188168. Retrieved 2013-04-23.
- Indichova, Julia. "Does a Low AMH Level (Anti-Mullerian Hormone) Indicate Infertility?". http://www.fertileheart.com. Retrieved 6 February 2015.
- Trbovich AM, Martinelle N, O'Neill FH, Pearson EJ, Donahoe PK, Sluss PM, Teixeira J (October 2004). "Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance". The Journal of Steroid Biochemistry and Molecular Biology 92 (3): 199–208. doi:10.1016/j.jsbmb.2004.07.002. PMID 15555913.
- Wang PY, Protheroe A, Clarkson AN, Imhoff F, Koishi K, McLennan IS (April 2009). "Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior". Proceedings of the National Academy of Sciences of the United States of America 106 (17): 7203–8. doi:10.1073/pnas.0902253106. PMC 2678437. PMID 19359476.
- Kelsey TW, Wright P, Nelson SM,Anderson RA, Wallace WHB (2011). Vitzthum, Virginia J, ed. "A validated model of serum anti-Müllerian hormone from conception to menopause". PLoS ONE 6 (7): e22024. doi:10.1371/journal.pone.0022024. PMC 3137624. PMID 21789216.
- La Marca, A.; Sunkara, S. K. (2013). "Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice". Human Reproduction Update 20 (1): 124–40. doi:10.1093/humupd/dmt037. PMID 24077980.
- Broer, S. L.; Broekmans, F. J. M.; Laven, J. S. E.; Fauser, B. C. J. M. (2014). "Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications". Human Reproduction Update 20 (5): 688–701. doi:10.1093/humupd/dmu020. ISSN 1355-4786.
- For mass values:
- Anti-Müllerian Hormone (AMH), Serum from Mayo Medical Laboratories. Retrieved April 2012.
- Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS (July 2012). "The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys". The Journal of Clinical Endocrinology and Metabolism 97 (7): 2450–5. doi:10.1210/jc.2012-1213. PMID 22508713. Retrieved 2013-04-23.
- Fertility: assessment and treatment for people with fertility problems. NICE clinical guideline CG156 - Issued: February 2013
- Iliodromiti, S.; Kelsey, T. W.; Wu, O.; Anderson, R. A.; Nelson, S. M. (2014). "The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature". Human Reproduction Update 20 (4): 560–570. doi:10.1093/humupd/dmu003. ISSN 1355-4786.
- Nelson SM, Yates RW et al. (2007). "Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy". Human Reproduction 22 (9): 2414–2421. doi:10.1093/humrep/dem204. PMID 17636277.
- Nelson SM, Yates RW et al. (2009). "Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception". Human Reproduction 24 (4): 867–875. doi:10.1093/humrep/den480.
- Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ (2011). "AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis". Human Reproduction Update 17 (1): 46–54. doi:10.1093/humupd/dmq034. PMID 20667894. Retrieved 2013-04-23.
- Seifer DB, Maclaughlin DT (September 2007). "Müllerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance". Fertil. Steril. 88 (3): 539–46. doi:10.1016/j.fertnstert.2007.02.014. PMID 17559842.
- Wallace WHB, Kelsey TW (2004). "Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography". Human Reproduction 19 (7): 1612–7. doi:10.1093/humrep/deh285. PMID 15205396.
- Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, Beckmann MW, Strissel P (December 2007). "Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes". Eur. J. Med. Res. 12 (12): 604–8. PMID 18024272.
- Dewailly, D.; Lujan, M. E.; Carmina, E.; Cedars, M. I.; Laven, J.; Norman, R. J.; Escobar-Morreale, H. F. (2013). "Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society". Human Reproduction Update 20 (3): 334–352. doi:10.1093/humupd/dmt061. ISSN 1355-4786. PMID 24345633.